The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its legacy within the broader industry now raises questions about long-term gains. Copycat versions are undercutting exclusivity , prompting concerns that investing in companies closely tied to Viagra's former position could be a speculative decis